Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases

Cliniques universitaires Saint-Luc- Université Catholique de Louvain100 enrolled

Overview

Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population. .

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Diabetes Obesity & Overweight Cushing Syndrome Metabolic Diseases Endocrine Diseases Sarcopenia Sarcopenic Obesity

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Metabolic or endocrine disease Exclusion Criteria: * Known myopathy * Systemic steroid use (\> 1 mg/kg hydrocortisone) or exogenous Cushing's syndrome * Psychological, family, sociological or geographical conditions that could potentially limit compliance with the study protocol * History of cancer within the five years prior to the study or Cushing's syndrome due to ACTH-secreting tumor

Outcomes

Primary Outcomes

Prevalence of sarcopenia / sarcopenic obesity

Time frame: From February 2026 to december 2056

Secondary Outcomes

Myokines levels in serum or plasma

Myokines levels in serum or plasma as measured by ELISA

Time frame: February 2026 to December 2056

Myokine expression

Myokine expression in muscle as measured by RT-qPCR or RNA-Seq

Time frame: February 2026 to December 2056

Prevalence of MASLD

MASLD as evaluated by Fibroscan, based on controlled attenuation parameter (CAP, in decibels per meter) as a marker of hepatic steatosis

Time frame: March 2026 to December 2056

Prevalence of MASH

Prevalence of MASH as evaluated by Fibroscan, based on Liver stiffness measurement (LSM, in kilopascals) as a surrogate of liver fibrosis